UNII,MainDrug,NDC,Strength,Formulation,INGREDIENT_NAME,ROUTE,DOSAGE_FORM,CAS_NUMBER,POTENCY_AMOUNT,POTENCY_UNIT,MAXIMUM_DAILY_EXPOSURE,MAXIMUM_DAILY_EXPOSURE_UNIT,RECORD_UPDATED
C151H8M554,pembrolizumab,0006-3029,50 mg  in 2 mL," injection, powder, lyophilized, for solution",SUCROSE,INTRAVENOUS,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",57501.0,,,2000.0,mg,
6OZP39ZG8H,pembrolizumab,0006-3029,50 mg  in 2 mL," injection, powder, lyophilized, for solution",POLYSORBATE 80,INTRAVENOUS,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",9005656.0,,,900.0,mg,
55X04QC32I,pembrolizumab,0006-3029,50 mg  in 2 mL," injection, powder, lyophilized, for solution",SODIUM HYDROXIDE,INTRAVENOUS,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",1310732.0,78.36,mg,,,
QTT17582CB,pembrolizumab,0006-3029,50 mg  in 2 mL," injection, powder, lyophilized, for solution",HYDROCHLORIC ACID,INTRAVENOUS,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",7647010.0,160.0,mg,,,
C151H8M554,pembrolizumab,0006-3026,25 mg  in 1 mL," injection, solution",SUCROSE,INTRAVENOUS,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",57501.0,,,2000.0,mg,
6OZP39ZG8H,pembrolizumab,0006-3026,25 mg  in 1 mL," injection, solution",POLYSORBATE 80,INTRAVENOUS,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",9005656.0,,,900.0,mg,
